High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy.
暂无分享,去创建一个
T. Asselah | P. Marcellin | D. Valla | D. Vidaud | N. Boyer | M. Bourlière | D. Cazals‐Hatem | M. Martinot-Peignoux | R. Moucari | M. Ripault | Ahmed El Ray | V. Oulès | M. Bourliere
[1] P. Marcellin,et al. Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C , 2006, Journal of viral hepatitis.
[2] H. Wedemeyer,et al. Treating viral hepatitis C: efficacy, side effects, and complications , 2006, Gut.
[3] L. Messerini,et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. , 2006, Gastroenterology.
[4] P. Adeleine,et al. Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). , 2006, Journal of hepatology.
[5] M. Manns,et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. , 2006, Journal of hepatology.
[6] X. Forns,et al. Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C , 2006, Hepatology.
[7] T. Asselah,et al. STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER? , 2005, Gut.
[8] M. Richardson,et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1 , 2005, Gut.
[9] E. Bini,et al. A Randomized Trial of Pegylated Interferon α-2b Plus Ribavirin in the Retreatment of Chronic Hepatitis C , 2005, The American Journal of Gastroenterology.
[10] D. Dhumeaux,et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. , 2005, Journal of hepatology.
[11] T. Ashikaga,et al. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. , 2005, Journal of hepatology.
[12] P. Marcellin,et al. Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis , 2005, Journal of viral hepatitis.
[13] B. Neuschwander‐Tetri,et al. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[14] R. Andrade,et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. , 2005, Gastroenterology.
[15] I. Siddique,et al. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin. , 2004, Antiviral therapy.
[16] William M. Lee,et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. , 2004, Gastroenterology.
[17] P. Marcellin,et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.
[18] S. Zeuzem. Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well? , 2004, Annals of Internal Medicine.
[19] J. McHutchison,et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. , 2004, Journal of hepatology.
[20] T. Berg,et al. Randomized, controlled trial with IFN-α combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C , 2003 .
[21] M. Manns,et al. Early virologic response to treatment with peginterferon alfa‐2b plus ribavirin in patients with chronic hepatitis C , 2003, Hepatology.
[22] M. Shiffman. Retreatment of patients with chronic hepatitis C , 2002, Hepatology.
[23] K. Reddy,et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). , 2002, Journal of hepatology.
[24] T. Berg,et al. Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy , 2002, Hepatology.
[25] Kenneth Koury,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[26] E. Schiff,et al. A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C , 2001, Hepatology.
[27] G. Tomlinson,et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C , 2003, Hepatology.
[28] B. Bacon,et al. Combination of interferon and ribavirin in chronic hepatitis C: Re‐treatment of nonresponders to interferon , 2001, Hepatology.
[29] S. Goodman,et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. , 2001, JAMA.
[30] J. Wong,et al. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: A meta‐analysis of controlled and uncontrolled trials , 2001, Hepatology.
[31] M. Shiffman,et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. , 2000, The New England journal of medicine.
[32] J. Reichen,et al. Peginterferon alfa-2a in patients with chronic hepatitis C. , 2000, The New England journal of medicine.
[33] J. Albrecht,et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. , 2000, Gastroenterology.
[34] J. Hoefs,et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[35] William M. Lee,et al. Early Hepatitis C virus–RNA responses predict interferon treatment outcomes in chronic hepatitis C , 1998, Hepatology.
[36] P. Marcellin,et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. , 1998, Clinical biochemistry.
[37] P. Bedossa,et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.
[38] P. Bedossa,et al. An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.
[39] G. Giannelli,et al. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C. , 2005, The new microbiologica.
[40] Y. Jeong,et al. Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection , 2003 .